US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ophthotech

1.39

0.0000

Volume:- -

Turnover:- -

Market Cap:57.58M

PE:0.82

High:1.39

Open:1.39

Low:1.39

Close:1.39

52wk High:4.50

52wk Low:1.02

Shares:41.42M

Float Shares:26.61M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.70

EPS(LYR):1.70

ROE:--

ROA:--

PB:0.46

PE(LYR):0.82

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Ophthotech

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.ophthotech.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPHT/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OPHT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","market":"US","secType":"STK","nameCN":"Ophthotech","latestPrice":1.39,"timestamp":1567195200000,"preClose":1.39,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":26608262,"shares":41421548,"eps":1.7,"marketStatus":"Trading","change":0,"latestTime":"02-10 10:14:21 EST","open":1.39,"high":1.39,"low":1.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.7,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","floatShares":26608262,"roa":"--","roe":"--","lyrEps":1.702247,"shares":41421548,"dividePrice":0,"high":1.39,"amplitude":0,"preClose":1.39,"low":1.39,"week52Low":1.02,"pbRate":"0.46","week52High":4.5,"institutionHeld":0,"latestPrice":1.39,"eps":1.7,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.7,"open":1.39,"prevYearClose":1.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPHT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-26","symbol":"OPHT","fiscalQuarterEnding":"2018/12","expectedEps":-0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551157200000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2018-10-31","symbol":"OPHT","fiscalQuarterEnding":"2018/09","expectedEps":-0.43,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-0.41},{"market":"US","date":"2018-08-01","symbol":"OPHT","fiscalQuarterEnding":"2018/06","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2018-05-09","symbol":"OPHT","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2018-02-27","symbol":"OPHT","fiscalQuarterEnding":"2017/12","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1519707600000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OPHT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ophthotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.","exchange":"NASDAQ","name":"Ophthotech","nameEN":"Ophthotech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":null}}